Connect with us

Press Releases

Aurion Biotech Names Chief Regulatory Officer

Experienced industry executive to lead global regulatory initiatives.

mm

Published

on

Daniela Drago

Daniela Drago

(PRESS RELEASE) SEATTLE, BOSTON AND TOKYO — Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, announced it has appointed Daniela Drago, MS, PhD, RAC as chief regulatory officer. Dr. Drago will be based in Boston and direct the company’s global regulatory strategies.

“A natural-born leader, Daniela brings to Aurion Biotech both broad and deep insights – not only in ophthalmology, but also cell therapies, gene therapies and biologics,” said Greg Kunst, chief executive officer of Aurion Biotech. “She shares our vision, our values of grit, stewardship and transformation, and our sense of urgency. We are fortunate that she will be driving our global regulatory strategy as we fulfill our mission to cure blindness by developing a platform of advanced therapies.”

The company’s first candidate is a cell therapy for the treatment of corneal endothelial dysfunction, invented by world-renowned ophthalmic surgeon and research scientist Professor Shigeru Kinoshita and his distinguished colleagues at Kyoto Prefecture University of Medicine (KPUM) in Japan.

“Throughout my career, I have developed a passion for being in the trenches of drug development. Regenerative medicine is evolving rapidly, which offers challenges, but also invites opportunities,” said Dr. Drago. “Bringing life-changing treatments to patients in need is extremely fulfilling; it’s also the cornerstone objective of Aurion Biotech’s strategy. I am excited to join a mission-based team with the determination to not only treat, but potentially cure, ocular diseases.”

Daniela Drago’s career includes leadership roles in the pharmaceutical and biotech industries, consulting organizations, and academic institutions. She brings to Aurion Biotech nearly 20 years of experience and a strong track record of achievements and leadership in global regulatory affairs and drug development. Dr. Drago joins Aurion Biotech from Biogen, where she led the regulatory team responsible for development products in the United States. During her time at Biogen, she was also selected as a member of Biogen’s Gene Therapy R&D Steering Committee. Prior to Biogen, Dr. Drago spent six years at George Washington University’s School of Medicine and Health Sciences (GWU), where she held the concurrent roles of associate professor of clinical research and leadership, and director of regulatory affairs. Before GWU, Dr. Drago held positions of increasing responsibility at several companies, including Bausch & Lomb, Hoffmann-La Roche, and Vifor Pharma.

Advertisement

Dr. Drago is a member of the Regulatory Affairs Committee of the American Society of Gene and Cell Therapy (ASGCT). She holds a PhD in Chemistry from the Swiss Federal Institute of Technology (ETH Zurich), and a masters degree in Chemistry from the University of Messina, Italy.

SPONSORED VIDEO

Sponsored by Shamir

Customer Focused, Service Oriented, Forward Thinking

Shamir is the recognized world leader in custom-designed technology for life improvement, fashion, performance sports, occupational single vision, and progressive lenses. Our values, the driving force behind our ideas and actions, keep the ECP in the center. Every Shamir representative is personally committed to our customers’ vision, and to providing the best service and support to meet and exceed their expectations, all with a personal touch.

Click here for more information.

Promoted Headlines

Advertisement

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Facebook

Most Popular